Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.
Engerix-B [Hepatitis B Vaccine (Recombinant)] is GSK’s monovalent vaccine that protects children, adolescents, and adults against acute and chronic infections caused by all known strains of HBV. Following the 1986 debut of Merck’s hepatitis B offering, Recombivax HB, Engerix-B was the second recombinant HBV vaccine to receive FDA approval. Engerix-B also received market authorization in Canada in 1991 and the 5EU in 2000. It is marketed under the names Engerix-B Kinder/Engerix-B Erwachsene in Germany.
Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Engerix-B including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Engerix-B for top seven countries from 2012 to 2022.
Sales information covered for the US, Canada, France, Germany, Italy, Spain and the UK
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of Engerix-B performance
Obtain sales forecast for Engerix-B from 2012-2022 in the top seven countries (the US, Canada, France, Germany, Italy, Spain and the UK).
Sales of Engerix-B in the Prophylactic HBV Vaccines Market
The combined sales of Engerix-B were estimated at $32.3 million in 2012. By 2022, we project Engerix-B sales to fall to $18.9 million, with a negative Compound Annual Growth Rate (CAGR) of 5.2% over the course of the decade. These estimates cover the sales in the eight countries included in this report: the US, France, Germany, Italy, Spain, the UK, Japan, and Canada.
Key factors contributing to sales of Engerix-B will include:
The yeast-derived, recombinant HBsAg antigen makes accidental infection impossible and thus eliminates the HIV transmission concerns associated with the plasma-derived, first-generation HBV vaccines. Physicians are comfortable with Engerix-B’s strong safety profile and clinical performance.
Unlike the combination vaccines, Engerix-B can be given to infants at birth. This expanded indication gives Engerix-B an advantage over its competitors in markets that encourage the administration of the first dose of HBV vaccine shortly after birth.
Amidst unwarranted public skepticism towards the ability of the infant immune system to tolerate combination vaccines, Engerix-B is seen as a viable option for alternative vaccination schedules and immunization skeptics.